PN5 - 5MG

PN5 Peptide

PN5 is an antimicrobial peptide derived from Pinus densiflora (pine needle). As a cationic, amphiphilic peptide, it displays broad-spectrum activity against multidrug-resistant Gram-negative and Gram-positive bacteria. PN5 kills by membrane permeabilization via a toroidal pore model, rapidly disrupting bacterial integrity. Activity has been shown against MDR E. coli and carbapenem-resistant Pseudomonas aeruginosa, with no resistance detected across serial passages.^[1–3]

Antimicrobial Stability & Antibiofilm Activity

• Retains activity in the presence of elastase and shows no significant cytotoxicity to mammalian cells at therapeutic ranges.^[1,3]
• Demonstrates antibiofilm effects—disrupts established biofilms and inhibits biofilm formation in vitro and in vivo—relevant to device-associated and chronic infections.^[2,3]

Anti-Inflammatory & Immunomodulatory Effects

• In LPS-stimulated macrophages, PN5 suppresses pro-inflammatory cytokines via NF-κB and MAPK pathway inhibition.^[1,4]
• In an LPS + D-galactosamine septic shock model, PN5 reduced hepatic inflammation and improved survival.^[1]

Related Peptide Class Findings

• Connexin-43 mimetic Peptide5 shows neuroprotection and analgesia in traumatic spinal cord injury and neuropathic pain, including inhibition of the NLRP3 inflammasome and improved functional recovery.^[5–7]

Safety Profile

• Systemic Peptide5 in rodents showed no significant off-target effects, no changes in connexin expression in non-target tissues, and no systemic cytokine perturbation.^[5]
• Chemical modifications (e.g., phosphorylation, glycosylation, acylation) can improve stability/bioavailability and reduce side effects across bioactive peptide classes.^[8,9]

Summary

PN5 combines rapid, membrane-targeted killing of MDR pathogens with antibiofilm and anti-inflammatory activity, while related class data support translational potential and a favorable safety outlook. These properties position PN5 as a candidate for further development in infectious disease and inflammatory indications.^[1–10]

References

1. Kang DD, Park J, Park Y. Microbiol Spectr. 2022;10(5):e0149422.
2. Martinez M, Gonçalves S, Felício MR, et al. BBA Biomembranes. 2019;1861(7):1329-1337.
3. Martínez M, Polizzotto A, Flores N, et al. Microb Pathog. 2020;139:103886.
4. Avolio F, Martinotti S, Khavinson VK, et al. Int J Mol Sci. 2022;23(7):3607.
5. Mao Y, Nguyen T, Tonkin RS, et al. Exp Brain Res. 2017;235(10):3033-3048.
6. Tonkin RS, Bowles C, Perera CJ, et al. Exp Neurol. 2018;300:1-12.
7. Porel P, Hunjan G, Kaur N, et al. Metab Brain Dis. 2025;40(5):213.
8. Hou H, Wang J, Wang J, et al. J Biomed Nanotechnol. 2020;16(12):1687-1718.
9. Kang L, Han T, Cong H, et al. BioFactors. 2022;48(3):575-596.
10. Baig MH, Ahmad K, Saeed M, et al. Biomed Pharmacother. 2018;103:574-581.

All information provided is for research purposes only.

All COA’s avail upon request by email info@truformlabs.com.

All information provided is for research purposes only.

Storage & Handling (Research Use)

• Lyophilized (dry) peptide: Store sealed at −20 °C to −80 °C (long-term), desiccated and protected from light. Short-term (≤2–3 weeks) at 2–8 °C is acceptable.
• After reconstitution: Store at 2–8 °C and use within 7 days, or aliquot immediately and freeze at −20 °C to −80 °C for up to 3 months.
• Avoid degradation: Prepare small aliquots to prevent repeat freeze–thaw; keep solutions on ice during handling; minimize air/light exposure.
• Solvent & pH: Reconstitute per protocol (e.g., sterile saline or bacteriostatic water) ~pH 7.0–7.4; avoid reactive metals/oxidizers.
• Labeling: Note concentration, solvent, and prep date on all aliquots; follow lab SOPs and any lot-specific stability guidance.

All information provided is for research purposes only.